Anastasiia Alekseevna Mikhaylova

Ms. Anastasiia Alekseevna Mikhaylova

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YNYulia Nasykhova
Yulia Nasykhova
ZTZiravard Tonyan
Ziravard Tonyan
AMAnastasiia Alekseevna Mikhaylova
Anastasiia Alekseevna Mikhaylova
MDMaria Danilova
Maria Danilova
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin resistance and progressively reduced insulin secretion, which leads to impaired glucose utilization, dyslipidemia and hyperinsulinemia and progressive pancreatic beta cell dysfunction. The incidence of type 2 diabetes mellitus is increasing worldwide and nowadays T2D already became a global epidemic. The well-known interindividual variability of T2D drug actions such as biguanides, sulfonylureas/meglitinides, DPP-4 inhibitors/GLP1R agonists and SGLT-2 inhibitors may be caused, among other things, by genetic factors. Pharmacogenetic findings may aid in identifying new drug targets and obtaining in-depth knowledge of the causes of disease and its physiological processes, thereby, providing an opportunity to elaborate an algorithm for tailor or precision treatment. The aim of this article is to summarize recent progress and discoveries for T2D pharmacogenetics and to discuss the factors which limit the furthering accumulation of genetic variability knowledge in patient response to therapy that will allow improvement the personalized treatment of T2D.

30 June 2022 in Genes
Verified
Journal Article
Open access
PDF file
ZTZiravard Tonyan
Ziravard Tonyan
YNYulia Nasykhova
Yulia Nasykhova
MDMaria Danilova
Maria Danilova
YBYury Barbitoff
Yury Barbitoff
ACAnton Changalidi
Anton Changalidi
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
Type 2 diabetes (T2D) is a common chronic disease whose etiology is known to have a strong genetic component. Standard genetic approaches, although allowing for the detection of a number of gene variants associated with the disease as well as differentially expressed genes, cannot fully explain the hereditary factor in T2D. The explosive growth in the genomic sequencing technologies over the last decades provided an exceptional impetus for transcriptomic studies and new approaches to gene expression measurement, such as RNA-sequencing (RNA-seq) and single-cell technologies. The transcriptomic analysis has the potential to find new biomarkers to identify risk groups for developing T2D and its microvascular and macrovascular complications, which will significantly affect the strategies for early diagnosis, treatment, and preventing the development of complications. In this article, we focused on transcriptomic studies conducted using expression arrays, RNA-seq, and single-cell sequencing to highlight recent findings related to T2D and challenges associated with transcriptome experiments.

23 July 2022 in Genes
Verified
Journal Article
Open access
PDF file
YNYulia Nasykhova
Yulia Nasykhova
YBYury Barbitoff
Yury Barbitoff
ZTZiravard Tonyan
Ziravard Tonyan
MDMaria Danilova
Maria Danilova
INIvan A. Nevzorov
Ivan A. Nevzorov
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
Metformin is an oral hypoglycemic agent widely used in clinical practice for treatment of patients with type 2 diabetes mellitus (T2DM). The wide interindividual variability of response to metformin therapy was shown, and recently the impact of several genetic variants was reported. To assess the independent and combined effect of the genetic polymorphism on glycemic response to metformin, we performed an association analysis of the variants in ATM, SLC22A1, SLC47A1, and SLC2A2 genes with metformin response in 299 patients with T2DM. Likewise, the distribution of allele and genotype frequencies of the studied gene variants was analyzed in an extended group of patients with T2DM (n = 464) and a population group (n = 129). According to our results, one variant, rs12208357 in the SLC22A1 gene, had a significant impact on response to metformin in T2DM patients. Carriers of TT genotype and T allele had a lower response to metformin compared to carriers of CC/CT genotypes and C allele (p-value = 0.0246, p-value = 0.0059, respectively). To identify the parameters that had the greatest importance for the prediction of the therapy response to metformin, we next built a set of machine learning models, based on the various combinations of genetic and phenotypic characteristics. The model based on a set of four parameters, including gender, rs12208357 genotype, familial T2DM background, and waist–hip ratio (WHR) showed the highest prediction accuracy for the response to metformin therapy in patients with T2DM (AUC = 0.62 in cross-validation). Further pharmacogenetic studies may aid in the discovery of the fundamental mechanisms of type 2 diabetes, the identification of new drug targets, and finally, it could advance the development of personalized treatment.

31 December 2020 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
AMAnastasiia Alekseevna Mikhaylova
Anastasiia Alekseevna Mikhaylova
YNYulia Nasykhova
Yulia Nasykhova
AMA. I. Muravyov
A. I. Muravyov
AEAnastasia Efimenko
Anastasia Efimenko
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
To carry out research projects, clinical trials and other studies in the field of personalized medicine, it is necessary to have collections of high-quality biological samples of various types. With the development of biomedical technologies, the need for large collections of biological samples will grow every year, which necessitates the creation of various biobanks for standardized collection, storage and distribution of such samples. One of the goals of the National Association of Biobanks and Biobanking Specialists is the development of a network of Russian biobanks interacting with each other at various levels, as well as the development and implementation of organizational and legal tools for its regulation. It is required not only to standardize the access and exchange of biological samples and data, but also to create a unified terminology that will be used by biobanks throughout Russia. The main aim is to create an accurate, professional and legally correct tool containing information accessible and understandable to a wide range of researchers.

Verified
Journal Article
Open access
PDF file
ZTZiravard Tonyan
Ziravard Tonyan
YBYury Barbitoff
Yury Barbitoff
YNYulia Nasykhova
Yulia Nasykhova
MDMaria Danilova
Maria Danilova
PKPolina Kozyulina
Polina Kozyulina
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
Type 2 diabetes mellitus (T2D) is a chronic metabolic disease characterized by insulin resistance and β-cell dysfunction and leading to many micro- and macrovascular complications. In this study we analyzed the circulating miRNA expression profiles in plasma samples from 44 patients with T2D and 22 healthy individuals using next generation sequencing and detected 229 differentially expressed miRNAs. An increased level of miR-5588-5p, miR-125b-2-3p, miR-1284, and a reduced level of miR-496 in T2D patients was verified. We also compared the expression landscapes in the same group of patients depending on body mass index and identified differential expression of miR-144-3p and miR-99a-5p in obese individuals. Identification and functional analysis of putative target genes was performed for miR-5588-5p, miR-125b-2-3p, miR-1284, and miR-496, showing chromatin modifying enzymes and apoptotic genes being among the significantly enriched pathways.

26 March 2024 in Journal of obstetrics and women's diseases
Verified
Journal Article
Closed access
PDF file
OTOlga E. Talantova
Olga E. Talantova
TPTatyana B. Postnikova
Tatyana B. Postnikova
AMAnastasiia Alekseevna Mikhaylova
Anastasiia Alekseevna Mikhaylova
OBOlesya N. Bespalova
Olesya N. Bespalova
МАМихайлова Анастасия Алексеевна
Михайлова Анастасия Алексеевна
The article provides an overview current literature covering the issues of preconception carrier screening. Hereditary diseases make a large contribution to disability, deterioration in quality of life and reduction in life expectancy, primarily among the child population. Treatment and rehabilitation of patients with hereditary diseases is accompanied by serious economic costs, as well as psychological and social problems. In many countries, preference for preventive measures over treatment measures is enshrined in law. Awareness of preconception carrier screening among non-genetic doctors and the general population is currently very low. The development and introduction into practical healthcare of effective approaches to the prevention of hereditary diseases is of paramount importance in reproductive medicine. Conducting expanded carrier screening before pregnancy will allow for identifying in future parents the latent carriage of hereditary diseases responsible for infertility, miscarriage, infant or child mortality, and fetal development abnormalities, as well as formulating optimal tactics to prepare and introduce pregnancy, including the use of diagnostic and preventive measures.